BIZARRE: Biogen - What They Never Told You

Is Biogen Stock Outperforming the S&P 500?

Biogen has outpaced the broader S&P 500 Index over the past year, and analysts remain reasonably upbeat about the stock’s prospects.

Barchart · Sep 16

Is Wall Street Bullish or Bearish on Biogen Stock?

Biogen has notably outperformed the broader market over the past year, and analysts are moderately optimistic about the stock’s prospects.

Barchart · Aug 20

Alzheimer's Treatment Can Now Begin at Home with an Injection Instead of Months of Infusions

The FDA approved an at-home subcutaneous starting dose of lecanemab. Launch is planned for late August, and monitoring requirements remain unchanged.

Medical Daily · Aug 13

New experimental drug shows promise in slowing early Alzheimer’s

An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau

The Independent UK · Jul 14

FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drug

The US FDA approved an at-home starting dose for Eisai and Biogen's Alzheimer's drug. This new subcutaneous formulation allows patients to self-administer injections, improving access. Previously, patients received intravenous infusions, typically at clinics, for initial treatment. This approval differentiates Leqembi from competitor Kisunla's infusion-only requirement. The drug targets amyloid beta…

The Economic Times · Jul 14

Biogen's Q2 2026 Earnings: What to Expect

Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.

Barchart · Jul 9

How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

Barchart · Jun 10

Ionis Pharmaceuticals Eyes Big Year With TRYNGOLZA Decision, 5 Phase 3 Readouts

Ionis Pharmaceuticals (NASDAQ:IONS) highlighted a busy slate of regulatory decisions, clinical readouts and partnered programs during a presentation at RBC Capital Markets’ Global Healthcare Conference, with Chief Development Officer Holly Kordasiewicz saying the company is moving from recent launch

MarketBeat · May 26

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock

MarketBeat · May 22

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf

MarketBeat · May 20